Philip S Zeitler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/362124/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Relationship Between Continuous Glucose Monitoring and OGTT in Youth and Young Adults With Cystic Fibrosis. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e548-e560.	1.8	14
2	Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin. Pediatric Diabetes, 2022, 23, 183-193.	1.2	14
3	A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes. Pediatric Diabetes, 2022, 23, 173-182.	1.2	13
4	Youth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study. Pediatric Diabetes, 2022, 23, 439-446.	1.2	4
5	Deterioration of glycemic control in youth-onset type 2 diabetes: what are the early and late predictors?. Journal of Clinical Endocrinology and Metabolism, 2022, , .	1.8	8
6	Type 2 diabetes in youth: Rationale for use of offâ€label antidiabetic agents. Pediatric Diabetes, 2022, 23, 615-619.	1.2	2
7	Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes. New England Journal of Medicine, 2022, 387, 433-443.	13.9	43
8	Delayed glucose peak and elevated 1-hour glucose on the oral glucose tolerance test identify youth with cystic fibrosis with lower oral disposition index. Journal of Cystic Fibrosis, 2021, 20, 339-345.	0.3	16
9	Two-Year Treatment With Metformin During Puberty Does Not Preserve β-Cell Function in Youth With Obesity. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2622-e2632.	1.8	8
10	Development of type 2 diabetes in adolescent girls with polycystic ovary syndrome and obesity. Pediatric Diabetes, 2021, 22, 699-706.	1.2	21
11	Body Composition and Markers of Cardiometabolic Health in Transgender Youth on Gonadotropin-Releasing Hormone Agonists. Transgender Health, 2021, 6, 111-119.	1.2	13
12	Sustaining the Pediatric Endocrinology Workforce: Recommendations from the Pediatric Endocrine Society Workforce Task Force. Journal of Pediatrics, 2021, 233, 4-7.	0.9	15
13	Long-Term Complications in Youth-Onset Type 2 Diabetes. New England Journal of Medicine, 2021, 385, 416-426.	13.9	234
14	Body Composition and Markers of Cardiometabolic Health in Transgender Youth Compared With Cisgender Youth. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e704-e714.	1.8	24
15	Normal Hemoglobin A1c Variability in Early Adolescence: Adult Criteria for Prediabetes Should Be Applied with Caution. Journal of Pediatrics, 2020, 216, 232-235.	0.9	12
16	Evaluation of the longitudinal change in health behavior profiles across treatment groups in the TODAY clinical trial. Pediatric Diabetes, 2020, 21, 224-232.	1.2	8
17	Withdrawal of medications leads to worsening of <scp>OGTT</scp> parameters in youth with impaired glucose tolerance or <scp>recentlyâ€diagnosed</scp> type 2 diabetes. Pediatric Diabetes, 2020, 21, 1437-1446.	1.2	7
18	High prevalence of cardiometabolic risk features in adolescents with 47, <scp>XXY</scp> /Klinefelter syndrome. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2020, 184, 327-333.	0.7	15

#	Article	IF	CITATIONS
19	Depression in Girls With Obesity and Polycystic Ovary Syndrome and/or Type 2 Diabetes. Canadian Journal of Diabetes, 2020, 44, 507-513.	0.4	11
20	Pediatric Extrapolation in Type 2 Diabetes: Future Implications of a Workshop. Clinical Pharmacology and Therapeutics, 2020, 108, 29-39.	2.3	11
21	Lessons From Continuous Glucose Monitoring in Youth With Pre–Type 1 Diabetes, Obesity, and Cystic Fibrosis. Diabetes Care, 2020, 43, e35-e37.	4.3	2
22	The Impact of Obesity On Insulin Sensitivity and Secretion During Pubertal Progression: A Longitudinal Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2061-e2068.	1.8	30
23	β ―Cell function in obese children and adolescents with metabolic syndrome compared to isolated obesity. Pediatric Diabetes, 2019, 20, 861-870.	1.2	1
24	Predictors of response to insulin therapy in youth with poorlyâ€controlled type 2 diabetes in the TODAY trial. Pediatric Diabetes, 2019, 20, 871-879.	1.2	13
25	cgmanalysis: An R package for descriptive analysis of continuous glucose monitor data. PLoS ONE, 2019, 14, e0216851.	1.1	48
26	Screening for cystic fibrosisâ€related diabetes and prediabetes: Evaluating 1,5â€anhydroglucitol, fructosamine, glycated albumin, and hemoglobin A1c. Pediatric Diabetes, 2019, 20, 1080-1086.	1.2	18
27	Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course. Diabetologia, 2019, 62, 1761-1772.	2.9	200
28	Sex Differences in Effects of Obesity on Reproductive Hormones and Glucose Metabolism in Early Puberty. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4390-4397.	1.8	51
29	Exome sequencing of 20,791Âcases of type 2 diabetes and 24,440Âcontrols. Nature, 2019, 570, 71-76.	13.7	248
30	Progress in understanding youth-onset type 2 diabetes in the United States: recent lessons from clinical trials. World Journal of Pediatrics, 2019, 15, 315-321.	0.8	22
31	Testosterone Treatment in Infants With 47,XXY: Effects on Body Composition. Journal of the Endocrine Society, 2019, 3, 2276-2285.	0.1	31
32	Exposure to Diabetes in Utero Is Associated with Earlier Pubertal Timing and Faster Pubertal Growth in the Offspring: The EPOCH Study. Journal of Pediatrics, 2019, 206, 105-112.	0.9	16
33	Management of Adrenal Insufficiency Risk After Long-term Systemic Clucocorticoid Therapy in Duchenne Muscular Dystrophy: Clinical Practice Recommendations. Journal of Neuromuscular Diseases, 2019, 6, 31-41.	1.1	20
34	A randomized clinical trial to evaluate the single-dose pharmacokinetics, pharmacodynamics, and safety of sitagliptin in pediatric patients with type 2 diabetes. Pediatric Diabetes, 2019, 20, 48-56.	1.2	10
35	Hemoglobin A1c Accurately Predicts Continuous Clucose Monitoring–Derived Average Clucose in Youth and Young Adults With Cystic Fibrosis. Diabetes Care, 2018, 41, 1406-1413.	4.3	45
36	Youth-Onset Type 2 Diabetes. Contemporary Endocrinology, 2018, , 393-418.	0.3	0

#	Article	IF	CITATIONS
37	Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline. Journal of Cystic Fibrosis, 2018, 17, 783-790.	0.3	58
38	Comparison of Surgical and Medical Therapy for Type 2 Diabetes in Severely Obese Adolescents. JAMA Pediatrics, 2018, 172, 452.	3.3	130
39	Review of methods for measuring βâ€cell function: <scp>D</scp> esign considerations from the <scp>R</scp> estoring <scp>I</scp> nsulin <scp>S</scp> ecretion (<scp>RISE</scp>) <scp>C</scp> onsortium. Diabetes, Obesity and Metabolism, 2018, 20, 14-24.	2.2	71
40	Longitudinal follow up of dysglycemia in overweight and obese pediatric patients. Pediatric Diabetes, 2018, 19, 199-204.	1.2	27
41	Evaluation and Management of Youth-Onset Type 2 Diabetes: A Position Statement by the American Diabetes Association. Diabetes Care, 2018, 41, 2648-2668.	4.3	218
42	Oxandrolone Treatment Results in an Increased Risk of Gonadarche in Prepubertal Boys With Klinefelter Syndrome. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3449-3455.	1.8	16
43	Identifying the Critical Gaps in Research on Sex Differences in Metabolism Across the Life Span. Endocrinology, 2018, 159, 9-19.	1.4	25
44	Impact of Insulin and Metformin Versus Metformin Alone on β-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. Diabetes Care, 2018, 41, 1717-1725.	4.3	112
45	Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: I. Observations Using the Hyperglycemic Clamp. Diabetes Care, 2018, 41, 1696-1706.	4.3	127
46	Potential Effects of Bariatric Surgery and Reduced Interleukin 32 Levels on Type 2 Diabetes and Its Comorbidities—Reply. JAMA Pediatrics, 2018, 172, 986.	3.3	0
47	Adrenal Insufficiency in Pediatric Eosinophilic Esophagitis Patients Treated with Swallowed Topical Steroids. Pediatric, Allergy, Immunology, and Pulmonology, 2017, 30, 135-140.	0.3	37
48	Alternate glycemic markers reflect glycemic variability in continuous glucose monitoring in youth with prediabetes and type 2 diabetes. Pediatric Diabetes, 2017, 18, 629-636.	1.2	22
49	Youth-Onset Type 2 Diabetes Consensus Report: Current Status, Challenges, and Priorities. Diabetes Care, 2016, 39, 1635-1642.	4.3	280
50	Advances in the Interdisciplinary Care of Children with Klinefelter Syndrome. Advances in Pediatrics, 2016, 63, 15-46.	0.5	55
51	Update on Youth-Onset Type 2 Diabetes. Advances in Pediatrics, 2016, 63, 195-209.	0.5	8
52	Insulin Resistance of Puberty. Current Diabetes Reports, 2016, 16, 64.	1.7	199
53	Screening for type 2 diabetes and prediabetes in obese youth: evaluating alternate markers of glycemiaA-Â1,5-anhydroglucitol, fructosamine, and glycated albumin. Pediatric Diabetes, 2016, 17, 206-211.	1.2	33
54	Presentation and effectiveness of early treatment of type 2 diabetes in youth: lessons from the TODAY study. Pediatric Diabetes, 2016, 17, 212-221.	1.2	52

#	Article	IF	CITATIONS
55	Metabolic syndrome is common and persistent in youth-onset type 2 diabetes: Results from the TODAY clinical trial. Obesity, 2015, 23, 1357-1361.	1.5	26
56	The eXtraordinarY Kids Clinic: an interdisciplinary model of care for children and adolescents with sex chromosome aneuploidy. Journal of Multidisciplinary Healthcare, 2015, 8, 323.	1.1	30
57	Clinical Trials in Youth-Onset Type 2 Diabetes: Needs, Barriers, and Options. Current Diabetes Reports, 2015, 15, 28.	1.7	20
58	HbA1c After a Short Period of Monotherapy With Metformin Identifies Durable Glycemic Control Among Adolescents With Type 2 Diabetes. Diabetes Care, 2015, 38, 2285-2292.	4.3	53
59	Type 2 diabetes in the child and adolescent. Pediatric Diabetes, 2014, 15, 26-46.	1.2	152
60	Hemoglobin A1c assay variations and implications for diabetes screening in obese youth. Pediatric Diabetes, 2014, 15, 557-563.	1.2	19
61	A Clinical Trial to Maintain Glycemic Control in Youth with Type 2 Diabetes. New England Journal of Medicine, 2012, 366, 2247-2256.	13.9	790
62	Hyperglycemic Hyperosmolar Syndrome in Children: Pathophysiological Considerations and Suggested Guidelines for Treatment. Journal of Pediatrics, 2011, 158, 9-14.e2.	0.9	110
63	Characteristics of Adolescents and Youth with Recent-Onset Type 2 Diabetes: The TODAY Cohort at Baseline. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 159-167.	1.8	378
64	Insulin Resistance in Adolescents with Type 1 Diabetes and Its Relationship to Cardiovascular Function. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 513-521.	1.8	258
65	Approach to the Obese Adolescent with New-Onset Diabetes. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 5163-5170.	1.8	21
66	Considerations Regarding the Diagnosis and Treatment of Childhood Type 2 Diabetes. Postgraduate Medicine, 2010, 122, 89-97.	0.9	6
67	Cardiovascular Risk Factors Among Youth With and Without Type 2 Diabetes. Diabetes Care, 2009, 32, 175-180.	4.3	61
68	Type 2 diabetes in children and adolescents. Pediatric Diabetes, 2009, 10, 17-32.	1.2	126
69	The metabolic syndrome and nonalcoholic fatty liver disease in children. Current Opinion in Pediatrics, 2009, 21, 529-535.	1.0	75
70	Prevention and Screening for Type 2 Diabetes in Youth. Endocrine Research, 2008, 33, 73-91.	0.6	1
71	Type 2 Diabetes in Children and Adolescents: Treatment. Obesity Management, 2007, 3, 216-221.	0.2	0
72	Type 2 Diabetes in Children and Adolescents: Clinical Features. Obesity Management, 2007, 3, 170-173.	0.2	0

#	Article	lF	CITATIONS
73	Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet, The, 2007, 369, 1823-1831.	6.3	331
74	Type 2 Diabetes in Children and Adolescents: Diagnosis and Typology. Obesity Management, 2007, 3, 125-127.	0.2	0
75	The global spread of type 2 diabetes mellitus in children and adolescents. Journal of Pediatrics, 2005, 146, 693-700.	0.9	540
76	Antagonism of Endogenous Growth Hormone-Releasing Hormone (GHRH) Leads to Reduced Proliferation and Apoptosis in MDA231 Breast Cancer Cells. Endocrine, 2002, 18, 85-90.	2.2	22
77	Stimulation of Mitogen-Activated Protein Kinase Pathway in Rat Somatotrophs by Growth Hormone-Releasing Hormone. Endocrine, 2000, 12, 257-264.	2.2	30
78	Type 2 Diabetes in Adolescents, No Longer Rare. Pediatrics in Review, 1998, 19, 434-435.	0.2	3
79 _	Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. Journal of	0.9	1,015